98%
921
2 minutes
20
Objective: To define the planning target volume (PTV) margins in intensity-modulated radiotherapy (IMRT) for prostate cancer without imaging guidance using B-mode acquisition and targeting (BAT) ultrasound-based prostate localization.
Methods: Ten patients with prostate cancer underwent BAT ultrasound alignment before each IMRT session. The set-up deviations, each consisting of isocenter displacements in 3 directions (anterior-posterior, right-left lateral, and superior-inferior), were recorded for a total of 225 times and analyzed with Kolmogorov-Smimov (K-S) method.
Results: The isocenter shift in each direction, which represented an average from all the patients, was 3.56∓2.71 mm, 4.08∓3.99 mm, and 3.20∓2.92 mm in the lateral (RL), anteroposterior (AP), and superior-inferior (SI) dimensions, respectively, and the deviations in each direction conformed to a normal distribution (P=0.806, P=0.061, and P=0.106, respectively). In the absence of imaging guidance for IMRT for prostate cancer, the PTV margin should expand by 8.97 mm in the right, 1.87 mm in the left, 12.05 mm in the anterior, 3.91 mm in the posterior, 9.06 mm in the superior and 2.66 mm in the inferior to allow 95% isodose curve to cover 90% of the clinical target volume.
Conclusion: The ultrasound imagining guided localization, with simple operation, nonirradiation and small systemic error, can be real-time corrected.
Download full-text PDF |
Source |
---|
BMC Urol
September 2025
Department of Radiology, Osaka Proton Therapy Clinic, 1-27-9 Kasugade naka, Osaka konohana-ku, Osaka, 554-0022, Japan.
Int Urol Nephrol
September 2025
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.
View Article and Find Full Text PDFBr J Cancer
September 2025
Institute of Life Sciences, Bhubaneswar, Odisha, India.
Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.
Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, University of California Irvine, Irvine, CA, USA.
Eur Urol Focus
September 2025
Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.
Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).